Levetiracetam, seizures, and suicidality

Harvard Review of Psychiatry

Volumn 19, Issue 1, 2011, Pages 47-55

  Givon, Lior ^a,b   Porter, Steven ^a   Padmanabhan, Bharanidharan ^a,b   Goren, Jessica ^a,b   Cohen, Pieter A ^a,b   Mills, Barry ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CAMBRIDGE HEALTH ALLIANCE   (United States)

^c NONE

Author keywords

Adverse drug reaction; anticonvulsant; levetiracetam; seizures; suicide; violence

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; ETIRACETAM; FLUOXETINE; LIVER ENZYME; VALPROIC ACID;

ADULT; ALCOHOL ABUSE; ANGER; ANXIETY; ARTICLE; ASTHMA; BRAIN VENTRICLE PERITONEUM SHUNT; CASE REPORT; CHILD ABUSE; COGNITIVE DEFECT; DEPRESSION; HUMAN; INSOMNIA; MAJOR DEPRESSION; MALE; MIGRAINE; MOOD DISORDER; PANIC; PRIORITY JOURNAL; SEIZURE; SLEEP DISORDER; SUDDEN INFANT DEATH SYNDROME; SUICIDAL IDEATION; SUICIDE;

EID: 79952920048     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.3109/10673229.2011.549777     Document Type: Article

References (59)

1. Brookshire BL, Fletcher JM, Mohan TP, Landry SH, Davidson KC, Francis DJ. Verbal and nonverbal skill discrepancies in children with hydrocephalus: A five-year longitudinal followup. J Pediatr Psychol 1995;20:785-800. (Pubitemid 26001822)
2. Vendrame M, Alexopoulos AV, Boyer K, et al. Longer duration of epilepsy and earlier age at epilepsy onset correlate with impaired cognitive development in infancy. Epilepsy Behav 2009;16:431-5.
3. Kaaden S, Helmstaedter C. Age at onset of epilepsy as a determinant of intellectual impairment in temporal lobe epilepsy. Epilepsy Behav 2009;15:213-7.
4. Huang CW, Pai MC, Tsai JJ. Comparative cognitive effects of levetiracetam and topiramate in intractable epilepsy. Psychiatry Clin Neurosci 2008;62:548-53.
5. Wu T, Chen CC, Chen TC, et al. Clinical efficacy and cognitive and neuropsychological effects of levetiracetam in epilepsy: An open-label multicenter study. Epilepsy Behav 2009;16:468-74.
6. SchmidtD.Drug treatment of epilepsy: Opinions and limitation. Epilepsy Behav 2009;15:56-65.
7. Fuller-Thompson E, Brennenstuhl S. The association between depression and epilepsy in a national representative sample. Epilepsia 2008;49:1-8.
8. Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. Acta Neurol Scand 2004;110:207-20. (Pubitemid 39274055)
9. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G. Major depression is a risk factor for seizures in older adults. Ann Neurol 2000;47:246-9. (Pubitemid 30078574)
10. Jobe PC, Daily JW, Wernicke JF. A noradrenergic and serotonergic hypothesis of the linkage between epilepsy and affective disorders. Crit Rev Neurobiol 1999;13:317-56.
11. de Boer HM,MulaM, Sander JW. The global burden of epilepsy. Epilepsy Behav 2008;12:540-6.
12. Hermann BP, Whitman S, Wyler AR, Anton MT, Vanderzwagg R. Psychosocial predictors of psychopathology in epilepsy. Br J Psychiatry 1990;156:98-105. (Pubitemid 20028160)
13. Vazquez B, Devinsky O. Epilepsy and anxiety. Epilepsy Behav 2003;4 suppl 4:S20-5. (Pubitemid 38035415)
14. McCagh J, Fisk JE, Baker GA. Epilepsy, psychosocial and cognitive functioning. Epilepsy Res 2009;86:1-14.
15. Kalinin VV. Suicidality and antiepileptic drugs. Drug Saf 2007;30:123-42.
16. Tellez-Zenteno J, Patten SB, Jette N, Williams J, Wieb S. Psychiatric comorbidities in epilepsy: A population-based analysis. Epilepsia 2007;48:2336-44. (Pubitemid 350243401)
17. Verrotti A, Cicconetti A, Scorrano B, et al. Epilepsy and suicide: Pathogenesis, risk factors, and prevention. Neuropsychiatr Dis Treat 2008;4:365-70. (Pubitemid 351711931)
18. Pompili M, Girardi P, Tatarelli R. Death from suicide versus mortality from epilepsy in the epilepsies: A meta-analysis. Epilepsy Behav 2006;9:641-8. (Pubitemid 44804263)
19. UCB, Keppra package insert [prescribing information].
20. Mula M, Sander JW. Negative effects of antiepileptic drugs on mood of patients with epilepsy. Drug Saf 2007;30:555-67. (Pubitemid 47037315)
21. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology 2003;61:704-6. (Pubitemid 37082613)
22. U.S. Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research. Statistical review and evaluation: Antiepileptic drugs and suicidality. 23 May 2008. http://www.fda.gov/ohrms/ dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf
23. Faught RE, Weiner JR, Guerin A, Cunningham MC, Duh MS. Impact of nonadherence to antiepileptic drugs on health care utilization and costs: Findings from the RANSOM study. Epilepsia 2009;50:501-9.
24. Pourpak Z, Fazlollahi MR, Fatthi F. Understanding adverse drug reactions and drug allergies: Principles, diagnosis and treatment aspects. Recent Pat Inflamm Allergy Drug Discov 2008;2:24-46. (Pubitemid 351524320)
25. Post RM, Altshuler LL, Frye MA, et al. Preliminary observations on the effectiveness of levetiracetam in the open adjunctive treatment of refractory bipolar. J Clin Psychiatry 2005;63:370-4. (Pubitemid 40476761)
26. Grunze H, Langosch J, Born C, Schaub G,Walden J. Levetiracetam in the treatment of acute mania: An open, add-on study with an on-off-on design. J Clin Psychiatry 2003;64:781-4. (Pubitemid 36897214)
27. Papp LA. Safety and efficacy of levetiracetam for patients with panic disorder: Results of an open-label, fixed-flexible dose study. J Clin Psychiatry 2006;67:1573-6. (Pubitemid 44787440)
28. Kinrys G, Wygant LE, Pardo TB, Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 2006;67:211-4. (Pubitemid 43357466)
29. Cramer JA, de Rue K, Devinsky O, Edrich P, Trimble MR. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003;4:124-32. (Pubitemid 37184583)
30. Naranjo CA, Busto U, Sellers EM, et al. Amethod for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. (Pubitemid 12149145)
31. Bell GS, Sander JW. Suicide and epilepsy. Curr Opin Neurol 2009;22:174-8.
32. Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: A population-based casecontrol study. Lancet Neurol 2007;6:693-8. (Pubitemid 47058376)
33. Harris EC, Barraclough B. Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry 1997;170:205-28. (Pubitemid 27117683)
34. Fuller-Thomson E, Brennenstuhl S. The association between depression and epilepsy in a nationally representative sample. Epilepsia 2009;50:1051-8.
35. Moore JL, Elliott JO, Lu B, Klatte ET, Charyton C. Serious psychological distress among persons with epilepsy based on the 2005 California Health Interview Survey. Epilepsia 2009;50:1077-84.
36. Stefansson SB, Olafsson E, Hauser WA. Psychiatric morbidity in epilepsy: A case controlled study of adults receiving disability benefits. J Neurol Neurosurg Psychiatry 1998;64:238-41. (Pubitemid 28159808)
37. U.S. Department of Health and Human services. Food and Drug Administration. MedWatch: The FDA safety information and adverse event reporting program. 29 Sep 2010. http://www.fda.gov/Safety/MedWatch/default.htm
38. Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000;31:1207-11.
39. Hull PR, D'Arcy C. Isotretinoin use and subsequent depression and suicide. Am J Clin Dermatol 2003;4:493-505. (Pubitemid 36871767)
40. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-9. (Pubitemid 43345358)
41. The smoking cessation aids varenicline (marketed as Chantix) and bupropion (marketed as Zyban and generics). FDA Drug Saf Newsletter 2009;2:1-4.
42. FDA Endocrine and Metabolic Drugs Advisory Committee. Clinical Review of Safety and Efficacy. In: Rimonabant briefing document [FDA Briefing Document No. NDA-21-888]. 2007. http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1- fda-backgrounder.pdf
43. Kanner AM. Suicidality and epilepsy: A complex relationship that remains misunderstood and underestimated. Epilepsy Curr 2009;9:63-6.
44. Brent DA, Crumrine PK, Varma RR, Allan M, Allman C. Phenobarbital treatment andmajor depressive disorder in children with epilepsy. Pediatrics 1987;80:909-17. (Pubitemid 18020333)
45. Kalinin VV, Polyansky DA. Gender differences in risk factors of suicidal behavior in epilepsy. Epilepsy Behav 2005;6:424-9. (Pubitemid 40468434)
46. White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioral side effects: A case-control study. Neurology 2003;61:1218-21. (Pubitemid 37377540)
47. Schneeweiss S, Avorn J. Antipsychotic agents and sudden cardiac death-how should we manage the risk? N Engl J Med 2009;360:294-6.
48. U.S. Food and Drug Administration. Center for Drug Evaluation and Research. Information for healthcare professionals: Suicidal behavior and ideation and antiepileptic drugs. 3 Mar 2010. http://www.fda.gov/Drugs/ DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm100192.htm
49. U.S. Department of Health and Human Services. Food and Drug Administration. FDA news release. FDA requires warnings about risk of suicidal thoughts and behavior for antiepileptic medications. 18 Jun 2009. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2008/ucm116991.htm
50. Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: A pharmacodynamic interaction. Epilepsy Res 2002;48:217-9. (Pubitemid 34252906)
51. Carota A, Novy J, Rossetti AO. Symptomatic complex partial status epilepticus manifesting as utilization behavior of a mobile phone. Epilepsy Behav 2009;14:553-5.
52. Henriquez SA, Brett R, Alexander J, Pratt J, Roberts CW. Neuropsychiatric disease and Toxoplasma gondii infection. Neuroimmunomodulation 2009;16:122-33. Epub 2009 Feb 11.
53. Hernández-Fustes OJ, Marcourakis T, de Bittencourt PR. The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate. Rev Neurol 1999;28:1043-7. (Pubitemid 29516817)
54. Schulze-Bonhage A, Feil B, Fauser S, Homberg V. [Levetiracetam in combined therapy for focal epilepsy: Experience with 80 patients]. Nervenarzt 2004;75:749-54. (Pubitemid 39141724)
55. Nakken KO, Eriksson AS, Lossius R, Johannessen SI. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy. Seizure 2003;12:42-6. (Pubitemid 36113762)
56. Szucs A, Clemens Z, Jakus R, et al. The risk of paradoxical levetiracetam effect is increased in mentally retarded patients. Epilepsia 2008;49:1174-9. (Pubitemid 351991396)
57. Kossoff EH, Dorward JL. The modified Atkins diet. Epilepsia 2008;49 suppl 8:37-41.
58. Liu L, Henry JC. New-onset partial epilepsy in adults. Curr Treat Options Neurol 2009;11:242-52.
59. Ben-Menachem E. Vagus-nerve stimulation for the treatment of epilepsy. Lancet Neurol 2002;1:477-82. (Pubitemid 37159138)